Stratistics MRC에 따르면 세계 락타아제 시장은 2025년 3억 1,374만 달러, 2032년에는 5억 4,825만 달러에 이를 것으로 예측되며, 예측 기간 중 CAGR은 8.3%를 나타낼 전망입니다.
락타아제는 소장에서 생산되는 효소로, 우유와 유제품에 포함된 유당을 포도당과 갈락토오스의 두 가지 간단한 당으로 분해합니다. 유당불내증이 있는 사람들은 락타아제 생성이 감소하여 유제품을 섭취할 때 소화 장애를 겪게 됩니다. 락타아제의 보충제는 증상을 억제하기 위해서 자주 사용됩니다.
미국립생물공학정보센터(NCBI)에 따르면 세계 인구의 65% 가까이가 락타아제 결핍증의 경향이 있다고 합니다.
유당 불내증의 유병률 상승
소화기계의 문제를 안고 있는 사람들이 효율적인 치료법을 요구하고 있기 때문에 식품이나 의약품에 있어서의 락타아제 효소의 사용은 증가하고 있습니다. 또한, 과학 연구는 락타아제 보충제의 이점을 계속 강조하며 시장 진입을 촉진하고 있습니다. 정부 및 의료기관은 계발 캠페인을 적극적으로 추진하고 있어 시장의 성장을 더욱 뒷받침하고 있습니다.
엄격한 규제 요건
락타아제 기반 제품의 효능과 안전성을 보장하기 위해 제조업체는 엄격한 품질 관리 요구 사항을 충족해야 합니다. 또한 국제 무역 규제 준수는 시장 확대를 목표로 하는 기업의 복잡성을 증가시킵니다.
대체 유제품에 대한 수요 증가
식물 유래 우유와 유제품을 포함하지 않는 제품은 건강 지향과 유당 불내증 소비자들 사이에서 인기를 끌고 있습니다. 비건주의와 유연한 식단의 증가로 인해 유제품이 없는 옵션에 대한 수요가 더욱 증가하고 있습니다
대체 소화 보조제의 가용성
유당 불내증 소비자는 락타아제에 의존하지 않고 소화를 돕는 다양한 프로바이오틱스와 효소 보충제 중에서 선택할 수 있습니다. 문제를 해결하기 위해 발효 식품과 같은 자연 요법을 선호하는 소비자도 있습니다.
COVID-19의 영향
COVID-19의 대유행은 락타아제 시장에 다양한 영향을 주었으며, 생산, 유통, 소비자 수요에 영향을 주었습니다. 그러나 팬데믹 기간 동안 건강에 대한 인식이 높아지면서 소비자들은 소화기 건강 솔루션을 찾도록 유도하여 시장의 관심을 높였습니다. 팬데믹 후, 기능성 식품과 영양 보조 식품에 대한 수요가 계속되고, 락타아제 제품의 채택에 혜택을 가져오고 있습니다.
예측 기간 동안 중성 락타아제 부문이 최대가 될 전망
중성 락타아제 부문은 식품 및 제약 업계에 널리 적용되기 때문에 예측 기간 동안 최대 시장 점유율을 차지할 것으로 예측됩니다. 맛을 손상시키지 않고 소화성을 향상시킵니다. 중성 락타아제 효소는 유아 영양과 의료 용도에도 널리 이용되고 있습니다.
예측기간 동안 의약품 분야가 가장 높은 CAGR이 예상
예측 기간 동안 의약품 분야가 가장 높은 성장률을 보일 것으로 예측되고 있습니다.
예측 기간 동안 아시아태평양은 낙농업이 활발해 유당 불내증의 유병률이 상승하고 있기 때문에 최대 시장 점유율을 차지할 것으로 예측됩니다. 기관의 건강 의식을 촉진하는 정부의 규제는 이 지역 시장 확대에 더욱 기여하고 있습니다.
예측 기간 동안 북미는 가장 높은 CAGR을 나타낼 것으로 예상되지만, 이는 기능성 식품과 소화기계 건강 솔루션에 대한 소비자의 강한 기호에 의한 것입니다. 지역 전체 시장 확대를 추진하고 있습니다.
According to Stratistics MRC, the Global Lactase Market is accounted for $313.74 million in 2025 and is expected to reach $548.25 million by 2032 growing at a CAGR of 8.3% during the forecast period. Lactase is an enzyme produced in the small intestine that breaks down lactose, the sugar found in milk and dairy products, into two simpler sugars: glucose and galactose. This process is essential for proper digestion and absorption of lactose in the body. In individuals with lactose intolerance, lactase production is reduced, leading to digestive discomfort when consuming dairy. Lactase supplements are often used to help manage symptoms. It plays a vital role in maintaining healthy digestion, especially in early childhood.
According to the National Center for Biotechnology Information (NCBI), nearly 65% of the global population is prone to lactase deficiency.
Rising prevalence of lactose intolerance
The use of lactase enzymes in food and medication is increasing as people with digestive issues look for efficient remedies. Increased awareness regarding lactose intolerance has prompted consumers to look for dairy alternatives and digestive aids. Additionally, scientific research continues to highlight the benefits of lactase supplementation, encouraging greater market adoption. Governments and healthcare organizations are actively promoting awareness campaigns, further supporting market growth. Consequently, the rising prevalence of lactose intolerance is a major driver of the lactase market.
Stringent regulatory requirements
Rigorous quality control requirements must be met by manufacturers in order to guarantee the efficacy and safety of lactase-based products. The approval process for lactase formulations can be lengthy, leading to delays in product launches. Additionally, compliance with international trade regulations adds complexity for companies looking to expand their market reach. Variations in food and drug safety regulations across different regions further hinder seamless market penetration.
Increasing demand for dairy alternatives
Plant-based milk and dairy-free products have gained traction among health-conscious and lactose-intolerant consumers. Food manufacturers are actively incorporating lactase enzymes to improve the digestibility of dairy alternatives while maintaining taste and texture. The rise of veganism and flexitarian diets further fuels demand for dairy-free options. Companies investing in lactose-free product development are poised to capitalize on this expanding market segment. Advancements in food technology continue to enhance the quality and accessibility of dairy alternatives.
Availability of alternative digestion aids
Consumers with lactose intolerance can choose from various probiotics and enzyme supplements that aid digestion without relying on lactase. Additionally, dairy-free formulations eliminate the need for lactase-based solutions, potentially limiting market expansion. Some consumers prefer natural remedies such as fermented foods to manage lactose digestion issues. Continuous innovation in digestive health supplements may further increase competition within the market. Businesses must differentiate their products to maintain relevance amid evolving consumer preferences.
Covid-19 Impact
The COVID-19 pandemic had a mixed impact on the lactase market, influencing production, distribution, and consumer demand. Supply chain disruptions led to shortages in raw materials, temporarily affecting lactase enzyme availability. However, heightened health awareness during the pandemic encouraged consumers to seek digestive health solutions, boosting market interest. Post-pandemic, the demand for functional foods and nutraceuticals continues to rise, benefiting lactase product adoption. Moreover, research into immune-supportive food formulations increased, indirectly benefiting lactase-enhanced dairy products.
The neutral lactase segment is expected to be the largest during the forecast period
The neutral lactase segment is expected to account for the largest market share during the forecast period, due to its widespread application across food and pharmaceutical industries. This segment offers improved stability and functionality in diverse product formulations, enhancing digestibility without compromising taste. The neutral lactase enzyme is also widely utilized in infant nutrition and medical applications. Its ability to work efficiently across various pH conditions further strengthens its market appeal.
The pharmaceuticals segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the pharmaceuticals segment is predicted to witness the highest growth rate, driven by the rising awareness of lactose-related digestive disorders. Lactase enzymes are increasingly being incorporated into medications and dietary supplements to improve digestive health. Additionally, healthcare professionals recommend lactase-based treatments to enhance digestive enzyme balance in patients. Advancements in enzyme formulation technology further boost pharmaceutical applications for lactase enzymes.
During the forecast period, the Asia Pacific region is expected to hold the largest market share due to its thriving dairy industry and rising lactose intolerance prevalence. Countries such as China, India, and Japan are witnessing increased consumer interest in lactose-free dairy products. Government regulations promoting digestive health awareness further contribute to market expansion in this region. Additionally, advancements in enzyme manufacturing technology boost local production and innovation. The presence of major food and pharmaceutical companies accelerates market adoption and distribution strategies.
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to its strong consumer preference for functional food and digestive health solutions. The rising adoption of lactose-free products and dietary supplements fuels market expansion across the region. Companies in the U.S. and Canada are investing in research and development to enhance lactase enzyme formulations. Regulatory support for enzyme-based solutions contributes to market growth and innovation.
Key players in the market
Some of the key players profiled in the Lactase Market include DSM, Novozymes, Kerry Group plc, IFF, Advanced Enzyme Technologies, Amano Enzyme Inc., Chr. Hansen Holding A/S, Senson, Merck KGaA (Sigma-Aldrich), Antozyme Biotech Pvt. Ltd., Infinita Biotech Private Limited, Aumgene Biosciences, Biolaxi Enzymes Pvt. Ltd., Creative Enzymes, and Nature BioScience Pvt. Ltd.
In March 2025, DSM-firmenich Animal Nutrition & Health has announced a partnership with Zenkei Company Limited, a premier livestock nutrition company, to advance sustainability in Japan's feed and egg production sectors. The two organisations have signed a Memorandum of Understanding (MOU) to implement dsm-firmenich's Sustell(TM), the industry-leading life cycle assessment (LCA) platform to measure and improve the environmental footprint of animal proteins.
In March 2024, Denmark CET. University of California San Diego, among the world's top-20 research universities, and the global leader in biosolutions Novonesis are excited to launch the establishment of a leading research consortium aimed at setting a new standard for collaboration and accelerating discoveries and knowledge in Human Milk Oligosaccharides (HMOs) science.